On Friday, Shares of Nike Inc (NYSE:NKE), SUBTRACT -0.79% and closed at $51.62 in the last trading session. The last trading range of the stock ranges between $51.62 and $52.50. NIKE, Inc. (NKE) declared recently that Tom Peddie becomes the new VP, GM of North America, succeeding Joaquin Hidalgo, who has served in this role since July 2013 and will be taking a leave of absence to focus on his health. This change is effective right away.
Peddie, a 26-year Nike veteran, has held senior administration roles across Nike, counting VP North America Sales and VP Global Sales. He was formerly VP, GM of Emerging Markets and joined the North America team earlier this year as VP, GM of Integrated Marketplace, where he has led Nike’s holistic integrated market strategy in North America.
“Tom is a strong leader with a deep understanding of our consumer and the integrated marketplace,” said Elliott Hill, President of Geographies and Sales, Nike Brand. “He has proven time and again his ability to lead teams toward continued and profitable long-term growth and we look forward to his leadership in this important geography.”
JD.Com Inc (ADR)(NASDAQ:JD), jumped 0.88% and closed at $26.50 in the last trading session. The last trading range of the stock ranges between $26.27 and $26.78. The company’s Market capitalization is $38.58 Billion with the total Outstanding Shares of 2.89 billion. Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, in addition to diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners.
GoPro Inc (NASDAQ:GPRO), LOST -1.73% and closed at $13.60 in the last trading session. The last trading range of the stock ranges between $13.50 and $14.20. The company’s Market capitalization is $1.86 Billion with the total Outstanding Shares of 102.94 Million. During the 52-week trading session the minimum price at which share price traded, registered at $8.62 and reached to max level of $31.33. GoPro, Inc. (GPRO) recently declared that it will release its financial results for the third quarter of 2016, ended September 30, 2016, after the market closes on November 3, 2016.
GoPro administration will host a conference call and live webcast for analysts and shareholders on November 3, 2016 at 2 p.m. Pacific Time (5 p.m. Eastern Time) to discuss the Company’s financial results.